[1] Sing CW, Lin TC, Bartholomew S, et al.Global epidemiology of hip fractures: Secular trends in incidence rate, post-fracture treatment, and all-cause mortality[J]. J Bone Miner Res, 2023, 38(8): 1064-1075. [2] Ceolin C, Sella S, Simonato C, et al.Impact of multidimensional assessment on anti-fracture treatment decisions in patients with fragility hip fractures within a Fracture Liaison Service[J]. BMC Geriatr, 2025, 25(1): 338. [3] 杨朝旭,邢栋,张隆,等. 老年髋部骨折术后对侧髋部再骨折的发生率及危险因素分析[J]. 河北医科大学学报,2021,42(1):30-33. [4] Tsai YL, Wu CH, Li CC, et al.Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients[J]. Osteoporos Int, 2023, 34(10): 1783-1791. [5] Mahaisavariya C, Vanitcharoenkul E, Kitcharanant N, et al.Exploring the osteoporosis treatment gap after fragility hip fracture at a Tertiary University Medical Center in Thailand[J]. BMC Geriatr, 2023, 23(1): 70. [6] 许昊,王培文,李毅中,等. 骨密度检测对脆性髋部骨折患者骨质疏松诊疗率的影响[J]. 中华老年医学杂志,2017,36(7):784-787. [7] De Las Cuevas C, Peñate W. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting[J]. Int J Clin Health Psychol, 2015, 15(2): 121-129. [8] 林树峰,李毅中. 骨质疏松药物治疗率和依从性[J]. 中国骨质疏松杂志,2020,26(3):439-444. [9] Iconaru L, Smeys C, Baleanu F, et al.Osteoporosis treatment gap in a prospective cohort of volunteer women[J]. Osteoporos Int, 2020, 31(7): 1377-1382. [10] 郭启云,郭沐洁,张林,等. 中文版骨质疏松知识评价工具的信效度检验[J]. 中国实用护理杂志,2015,31(7):512-515. [11] 中华医学会骨科学分会创伤骨科学组. 中国脆性骨折术后规范化抗骨质疏松治疗指南(2021)[J]. 中华创伤骨科杂志,2021,23(02):93-101. [12] AbuAlrob H, Ioannidis G, Jaglal S, et al. Hip fracture rate and osteoporosis treatment in Ontario: A population-based retrospective cohort study[J]. Arch Osteoporos, 2024, 19(1): 53. [13] 宋咪,邱晨,邵梦琪,等. 老年髋部骨折患者术后抗骨质疏松药物治疗现状及关联因素分析:一项全国多中心现况调查研究[J]. 解放军医学院学报,2024,45(5):469-474. [14] Sturrock A, Grabrovaz M, Bullock L, et al.A person-centred primary care pharmacist-led osteoporosis review for optimising medicines (PHORM): A protocol for the development and co-design of a model consultation intervention[J]. BMJ Open, 2024, 14(11): 85323. [15] 何茂芯,杨玉洁. 维持性血液透析患者服用磷结合剂依从性调查分析[J]. 护理学杂志,2020,35(8):39-41. [16] Ahn SH, Park SY, Kwak MK, et al.Factors associated with compliance and persistence with pharmacotherapy in patients with osteoporosis: A nationwide cohort study in Korea[J]. J Korean Med Sci, 2025, 40(18): 72. [17] 古肖峰,皇甫晓,王冰. 运城市冠心病与缺血性脑卒中共病稳定期患者的二级预防用药依从性及其影响因素调查[J]. 华南预防医学,2024,50(5):459-461. [18] Shi W, Wu L, Li X, et al.Community-embedded follow-up management intervention for geriatric primary care: A mixed-methods study of an integrated health services model[J]. BMC Health Serv Res, 2024, 24(1): 298. [19] Mandl LA, Rajan M, Lipschultz RA, et al.The effect of social isolation on 1-year outcomes after surgical repair of low-energy hip fracture[J]. J Orthop Trauma, 2024, 38(4): 149-156. [20] McWilliam Ross K, Gilder RE. Changing osteoporosis knowledge and behaviors through structured education[J]. Orthop Nurs, 2023, 42(1): 14-19. [21] Ercan S, İnce Parpucu T, Başkurt Z, et al.Health belief model-male osteoporosis: A cross-sectional study[J]. Cent Eur J Public Health, 2023, 31(3): 184-190. [22] Watanabe N, Miyatake K, Takada R, et al.The prevalence and treatment of osteoporosis in patients undergoing total hip arthroplasty and the levels of biochemical markers of bone turnover[J]. Bone Joint Res, 2022, 11(12): 873-880. [23] 林华,夏维波. 双膦酸盐治疗骨质疏松症的依从性管理和药物假期选择[J]. 中华骨质疏松和骨矿盐疾病杂志,2020,13(2):103-109. |